Premium
Comparison of chlorambucil and streptonigrin (NSC‐45383) in the treatment of chronic lymphocytic leukemia
Author(s) -
Kaung David T.,
Whittington Richard M.,
Spencer Herbert H.,
Patno Mary E.
Publication year - 1969
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(196903)23:3<597::aid-cncr2820230311>3.0.co;2-c
Subject(s) - chlorambucil , medicine , chronic lymphocytic leukemia , toxicity , gastroenterology , chemotherapy , incidence (geometry) , bone marrow , leukemia , bone marrow suppression , cyclophosphamide , physics , optics
Abstract Forty‐nine men with progressive chronic lymphocytic leukemia were treated with chlorambucil 0.2 mg/kg/day orally or streptonigrin 0.004 mg/kg/day orally for a minimum of six weeks in a double‐blind study. Dosage modifications were frequently necessary to achieve maximum drug effect and prevent serious toxicity. Eighteen of 24 patients treated with chlorambucil (75%) and 21 of 25 patients treated with streptonigrin (84%) showed some objective response. The difference was not statistically significant. The incidence of bone marrow depression was comparable. Significantly more patients treated with streptonigrin had mild to moderate gastrointestinal toxicity.